🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The #HEAT is on. Update on #SCCHN treatment and discussion of our new #platform study for real-world data in Germany. Arbeitsgemeinschaft Internistische Onkologie - AIO

brief, crisp and straight from Chicago.

great group and detailed discussion. I hope you find it as enjoyable as I did.

Clinical trial question: If your patient is eligible for RCT, and field has equipoise, but you personally believe one arm is better than the other, you should: 1. Enroll on RCT. You don't know the answer. 2. Do what you think is best for your patient, even if evidence not there

Same for me. Inform the patient about the data, risks and benefits and let them decide

Uromigos welcome to our dear friends from Germany!

Thank you Petros. We navigated through football, American presidents and cancer studies✌️

Absolutely. Phantastic people and great experience.

Real-world #cabozantinib after ICI: 👉 similar efficacy (shorter OS) compared to METEOR 👉 62% had lower starting doses (<60mg) 👉 similar outcome in low vs. 60 mg starting dose 👉 less toxicity with lower dose 👉 let's re-think cabozantinib dosing Axel S. Merseburger Toni Choueiri, MD

#sunniforecast investigated whether IPI-NIVO is superior to SOC (mainly TKI single agent) in ncc-RCC subtypes. All pts. had central pathology. IPI-NIVO had superior OS and supports its role in these rare subtypes. The benefit in chRCC was unexpected. PD-L1+ had highest benefits

the study did not show a meaningful difference. DFS was improved in pts with higher risk of recurrence, such as sRCC, PDL1+ or T4. Getting patient populations right is of clinical interest and leads to stronger recommendations in these groups of patients in my daily practice

So true. IO2.0 is not simple and may require patient selection or other classes of agents to be involved

Great discussion Bladder Cancer with great Colleges @drdaaronPoon from mol Society of Uro-Oncology! However Great, unforunately I missed to meet Axel S. Merseburger , but potentially tomorrow @HKairport I meet my Mentor Viktor Grünwald; 3- Hannover Guys@hongkong?

Such a great meeting with excellent hosts and wonderful exchange of ideas

Big change in the treatment landscape and broad exposure of patients to IO. Really looking forward to see the data

Great work and so important to distinguish adeno from UC in urachal cancers. Totally different treatment paradigms

Big news! The European Medicines Agency’s Committee for Medicinal Products for Human Use approved Belzutifan for advanced kidney cancer and VHL disease: actionkidneycancer.org/belzutifan-app… #KidneyCancer Action Kidney Cancer

So great to enrich the the landscape. Big step forward for patients with VHL associated cancers.

#EAU25 Limitations of RMB for 'oncocytoma' 🔹68% actual oncocytoma on final pathology 🔹19% chromophobe RCC 🔹7% hybrid oncocytic/chromophobe tumor 📷Karim Bensalah UroToday.com

So important to have the expert pathology in rare diseases. Really key to proper management